Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical and Experimental Pharmacology and Physiology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1440-1681.12332PMID 25360831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type 2 diabetes mellitus

  2015cited by this paper
• Supplemental Figure 1

  2014cited by this paper
• Gut microbiota and nuclear receptors in bile acid and lipid metabolism

  2014cited by this paper
• SGLT-2 inhibitors as second-line therapy in type 2 diabetes.

  2014cited by this paper
• Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

  2014cited by this paper
• Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

  2014cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

  2013cited by this paper
• Taspoglutide, a once‐weekly glucagon‐like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open‐label randomized trial

  2013cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

  2013cited by this paper
• Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

  2013cited by this paper
• Metabolic Syndrome and Obesity : Targets and Therapy SGLT-2 inhibitors and their potential in the treatment of diabetes

  2013cited by this paper
• Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism

  2013cited by this paper
• Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

  2013cited by this paper
• A review of the efficacy and safety of oral antidiabetic drugs

  2013cited by this paper
• Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes

  2013cited by this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013influential reference
• Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

  2013cited by this paper
• Glucagon-like peptide 1 and appetite.

  2013cited by this paper
• Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus

  2013cited by this paper
• Canagliflozin: First Global Approval

  2013cited by this paper
• Canagliflozin for the treatment of type 2 diabetes.

  2013cited by this paper
• Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

  2013cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

  2013cited by this paper
• Antidiabetic agents: past, present and future.

  2013cited by this paper
• PPARγ signaling and metabolism: the good, the bad and the future

  2013cited by this paper
• Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive

  2013cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

  2013cited by this paper
• SGLT2 inhibitors for diabetes: turning symptoms into therapy.

  2013cited by this paper
• Mitiglinide for type 2 diabetes treatment

  2013cited by this paper
• Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.

  2013cited by this paper
• Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.

  2013cited by this paper
• A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

  2013cited by this paper
• Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• Dapagliflozin

  2012cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin

  2012cited by this paper
• Liraglutide: from clinical trials to clinical practice

  2012cited by this paper
• Bile acid sequestrants: more than simple resins

  2012cited by this paper
• Repaglinide

  2012cited by this paper
• Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

  2012cited by this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cited by this paper
• Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

  2012cited by this paper
• The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass‐spectrometric (UPLC‐MS/MS) method for such studies

  2012cited by this paper
• Cellular and molecular mechanisms of metformin: an overview.

  2012cited by this paper
• An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

  2012cited by this paper
• Metformin pathways: pharmacokinetics and pharmacodynamics

  2012cited by this paper
• α-Glucosidase inhibitors and their use in clinical practice

  2012cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Drug-induced hypoglycaemia in type 2 diabetes

  2012cited by this paper
• Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

  2012cited by this paper
• Linagliptin

  2012cited by this paper
• Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

  2012cited by this paper
• Incretin-based therapies

  2012cited by this paper
• Thiazolidinedione safety

  2012cited by this paper
• Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

  2011cited by this paper
• Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes

  2011cited by this paper
• Sitagliptin: a review

  2011cited by this paper
• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  2011cited by this paper
• Pramlintide and the treatment of diabetes: a review of the data since its introduction

  2011cited by this paper
• Liraglutide

  2011cited by this paper
• Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

  2010cited by this paper
• The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.

  2010cited by this paper
• Role of bile acid sequestrants in the treatment of type 2 diabetes.

  2010cited by this paper
• Adjunct therapy for type 1 diabetes mellitus

  2010influential reference
• Bromocriptine: old drug, new formulation and new indication

  2010cited by this paper
• Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind Study

  2010cited by this paper
• Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

  2010cited by this paper
• Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

  2009cited by this paper
• Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy

  2009cited by this paper
• Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

  2008cited by this paper
• Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy

  2008cited by this paper
• Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.

  2008cited by this paper
• A review of nateglinide in the management of patients with type 2 diabetes

  2007cited by this paper
• Meglitinide analogues for type 2 diabetes mellitus.

  2007cited by this paper
• Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.

  2007cited by this paper
• KATP channels as molecular sensors of cellular metabolism

  2006cited by this paper
• PPARdelta regulates glucose metabolism and insulin sensitivity.

  2006cited by this paper
• PPARδ regulates glucose metabolism and insulin sensitivity

  2006cited by this paper
• Are sulfonylureas passé?

  2006cited by this paper
• Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects.

  2003cited by this paper
• The pharmacokinetics of pioglitazone in patients with impaired renal function.

  2003cited by this paper
• Pramlintide for the Treatment of Diabetes Mellitus

  2003cited by this paper
• Modulation of Monoaminergic Neural Circuits

  2002cited by this paper
• Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression.

  2002cited by this paper
• Modulation of monoaminergic neural circuits: potential for the treatment of type 2 diabetes mellitus.

  2002cited by this paper
• Sulfonylurea stimulation of insulin secretion.

  2002cited by this paper
• Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.

  2001cited by this paper
• Pharmacokinetics and metabolism of nateglinide in humans.

  2001cited by this paper
• Aldose Reductase Inhibitors

  2001cited by this paper
• Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family

  2001cited by this paper
• Nateglinide: a new rapid-acting insulinotropic agent

  2001cited by this paper
• Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.

  2000cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.

  2000cited by this paper
• Pharmacokinetics of tolbutamide in ethnic Chinese.

  1999cited by this paper
• Clinical Pharmacokinetics of Troglitazone

  1999cited by this paper
• Molecular biology of adenosine triphosphate-sensitive potassium channels.

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper

• Bioequivalence and Pharmacokinetic Evaluation of Gliclazide Modified‐Release Tablets in Healthy Chinese Volunteers

  2026cites this paper
• Integrative proteomic analysis reveals the potential diagnostic marker and drug target for the Type‐2 diabetes mellitus

  2025cites this paper
• Synthetic advances towards the synthesis of canagliflozin, an antidiabetic drug.

  2025cites this paper
• Trends and patterns in antidiabetic medication prescriptions: Insights from Greece's electronic prescription database.

  2025cites this paper
• Comprehensive Review and Perspective on Fructose 1,6-Bisphosphatase Inhibitors for the Management of Type 2 Diabetes Mellitus

  2025cites this paper
• Optimized nonlinear robust controller along with model-parameter estimation for blood glucose regulation in type-1 diabetes.

  2025cites this paper
• Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients

  2024cites this paper
• Optimized Control Techniques for Improved Type 1 Diabetes Health Outcomes

  2024cites this paper
• Discovering the therapeutic potential of Naringenin in diabetes related to GLUT4 and its regulatory factors: a computational approach

  2024cites this paper
• Emodin derivatives as novel potent DPP-4 inhibitors: Design, synthesis, and in vitro evaluation.

  2024cites this paper
• Synthesis, characterization, DNA interaction, molecular docking, and α‐glucosidase inhibition studies of 3‐(pyrimidin‐2‐ylthio) groups substituted water soluble zinc (II) phthalocyanine

  2024cites this paper
• Synthesis, α-Glucosidase inhibitory activity and docking studies of Novel Ethyl 1,2,3-triazol-4-ylmethylthio-5,6-diphenylpyridazine-4-carboxylate derivatives

  2023cites this paper
• Medicinal Chemistry of Non-peptidomimetic Dipeptidyl Peptidase IV (DPP IV) Inhibitors for Treatment of Type-2 Diabetes Mellitus: Insights on Recent Development

  2023cites this paper
• Synthetic Approaches to Gliflozins: A Comprehensive Overview

  2023cites this paper
• Design, synthesis, biological evaluations and in silico studies of N-substituted 2,4-thiazolidinedione derivatives as potential a-glucosidase inhibitors

  2023cites this paper
• Benzophenone Semicarbazones as Potential alpha-glucosidase and Prolyl Endopeptidase Inhibitor: In-vitro free radical scavenging, enzyme inhibition, mechanistic, and molecular docking studies

  2023cites this paper
• และฤทธิ์ยับยั้งเอนไซม์แอลฟา-กลูโคซิเดส ของสารสกัดน ้าจากต้นเฉาก๊วย Antioxidant Activity and  -Glucosidase Inhibitory Activity of Mesona chinensis Aqueous Extract

  2023influential citation
• GLUT4 as A Protein Target for T2DM Therapy with Natural Compounds

  2023cites this paper
• Phytochemical profiling, anti-hyperglycemic, antifungal, and radicals scavenging potential of crude extracts of Athyrium asplenioides- an in-vitro approach.

  2023cites this paper
• Miglitol-PMO nanoparticles, an alpha-glucosidase inhibitor, has prolonged action on blood glucose level in diabetic rats

  2022cites this paper
• In silico identification of potential inhibitors from rumex vesicarius against DPP4 of diabetes mellitus

  2022cites this paper
• Design, Synthesis and Pharmacological Evaluation of 2-(3-BenzoyI-4-Hydroxy-1,1-Dioxido-2H-Benzo[e][1,2]thiazin-2-yI)-N-(2-Bromophenyl) Acetamide as Antidiabetic Agent

  2022cites this paper
• Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives

  2022cites this paper
• Hibiscus sabdariffa in Diabetes Prevention and Treatment—Does It Work? An Evidence-Based Review

  2022cites this paper
• Fucoidan-based hydrogels particles as versatile carriers for diabetes treatment strategies

  2022cites this paper
• Biological macromolecules as antidiabetic agents

  2022cites this paper
• Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids

  2021cites this paper
• Polyphenolic inhibition of enterocytic starch digestion enzymes and glucose transporters for managing type 2 diabetes may be reduced in food systems

  2021cites this paper
• Anti-diabetic Role of Adropin in Streptozotocin Induced Diabetic Rats via Alteration of PI3K/Akt and Insulin Signaling Pathway.

  2021cites this paper
• SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD.

  2021cites this paper
• One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus

  2021cites this paper
• Synthesis and biological evaluation of isatin derivatives containing 1,3,4-thiadiazole as potent a-glucosidase inhibitors.

  2021cites this paper
• New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies

  2021cites this paper
• 1,2,3-Triazole substituted phthalocyanine metal complexes as potential inhibitors for anticholinesterase and antidiabetic enzymes with molecular docking studies

  2020cites this paper
• Anti-diabetic drugs recent approaches and advancements.

  2020cites this paper
• Synthesis and characterisation of thiobarbituric acid enamine derivatives, and evaluation of their α-glucosidase inhibitory and anti-glycation activity

  2020cites this paper
• Structure Elucidation of Prenyl- and Geranyl-Substituted Coumarins in Gerbera piloselloides by NMR Spectroscopy, Electronic Circular Dichroism Calculations, and Single Crystal X-ray Crystallography

  2020cites this paper
• Antidiabetic effects of a lipophilic extract obtained from flowers of Wisteria sinensis by activating Akt/GLUT4 and Akt/GSK3β

  2020cites this paper
• Process Development of Sotagliflozin, a Dual Inhibitor of Sodium–Glucose Cotransporter-1/2 for the Treatment of Diabetes

  2020cites this paper
• IN VITRO STUDY ON ALPHA AMYLASE INHIBITORY ACTIVITY OF MURRYA KOENIGII: EFFECT OF EXTRACTION SOLVENTS

  2019cites this paper
• Alpha glucosidase inhibiting activity and in vivo antidiabetic activity of Fraxinus floribunda bark in streptozotocin-induced diabetic rats

  2019cites this paper
• Evaluation of the hypoglycemic effect of seven wild folkloric edible plants from Palestine

  2019cites this paper
• Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.

  2019cites this paper
• Process Development for a Locally Acting SGLT1 Inhibitor, LX2761, Utilizing sp3–sp2 Suzuki Coupling of a Benzyl Carbonate

  2019cites this paper
• ISOLATION OF AN ALPHA AMYLASE INHIBITOR FROM MURRYA KOENIGII LEAVES

  2019cites this paper
• Identification of α-Glucosidase Inhibitors in Machilus litseifolia by Combined Use of High-Resolution α-Glucosidase Inhibition Profiling and HPLC-PDA-HRMS-SPE-NMR.

  2019cites this paper
• Bio-inspired Strategies Against Diabetes and Associated Complications: A Review.

  2019cites this paper
• SEASONAL EFFECT ON IN VITRO ALPHA AMYLASE INHIBITORY ACTIVITY OF MURRYA KOENIGII LEAVES

  2019cites this paper
• Effect of Food on the Pharmacokinetics of Gliclazide 60 mg Modified Release Tablet in Healthy Caucasian Volunteers

  2018influential citation
• Synthesis of TMPA Derivatives through Sequential Ir(III)-Catalyzed C–H Alkylation and Their Antidiabetic Evaluation

  2018cites this paper
• SYNTHESIS, PHARMACOLOGICAL EVALUATION AND LIGAND-PROTEIN INTERACTION STUDY OF HYBRID UREA AND THIOUREA DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS

  2018cites this paper
• Pancreatic extracellular communication. Applications to beta cell cultures and islet amyloid polypeptide aggregation

  2018cites this paper
• Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.

  2018cites this paper
• 3D-Models of Insulin-Producing β-Cells: from Primary Islet Cells to Stem Cell-Derived Islets

  2017cites this paper
• Alpha-glucosidase inhibitory activity of Garcinia lateriflora Blume Leaves

  2017cites this paper
• New prospects for the development of selective inhibitors of α-glucosidase based on coumarin-iminothiazolidinone hybrids: Synthesis, in-vitro biological screening and molecular docking analysis

  2017cites this paper
• Caracterización del tratamiento farmacológico de personas con diabetes mellitus en la Ciudad de México

  2017cites this paper
• Protective effects of tea, red wine and cocoa in diabetes. Evidences from human studies.

  2017cites this paper
• Geniposide protects pancreatic β cells from high glucose‐mediated injury by activation of AMP‐activated protein kinase

  2017cites this paper
• Analogues of xanthones--Chalcones and bis-chalcones as α-glucosidase inhibitors and anti-diabetes candidates.

  2017cites this paper
• Synthesis of 3-acyloxyxanthone derivatives as α-glucosidase inhibitors: A further insight into the 3-substituents' effect.

  2016cites this paper
• A community-based lifestyle intervention program for adults with type 2 diabetes mellitus in a low socio-economic status community

  2016cites this paper
• An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass

  2016cites this paper
• Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition

  2015cites this paper
• Impact of Metformin on Male Reproduction.

  2015cites this paper
• An Overview of Metformin and Implications in the Workplace

  2015cites this paper
• Targeting metabolic disorders by natural products

  2015cites this paper
• Structural bioinformatics Identification of promising dipeptidyl peptidase-4 and protein tyrosine phosphatase 1B inhibitors from selected terpenoids through molecular modeling

  year unknowncites this paper